Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (14): 2633-2636.doi: 10.3969/j.issn.1673-8225.2012.14.033

Previous Articles     Next Articles

Immunoregulation and human umbilical cord blood-derived mesenchymal stem cells transplantation

Jiao Bao-liang1, Wang Jing-chuan1, Gao Bing-hua2, Wang Xin-sheng1   

  1. 1The First Clinical Medical College of Hebei North University, Zhangjiakou  075000, Hebei province, China; 2Department of Hematology, First Affiliated Hospital of Hebei North University, Zhangjiakou  075000, Hebei Province, China
  • Received:2011-09-22 Revised:2011-10-24 Online:2012-04-01 Published:2012-04-01
  • Contact: Gao Bing-hua, Chief physician, Department of Hematology, First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China gaobinghuaxueye@sina.com Wang Xin-sheng, Professor, Doctor, Master’s supervisor, the First Clinical Medical College of Hebei North University, Zhangjiakou 075000, Hebei Province, China wxinsheng1968@sina.com
  • About author:Jiao Bao-liang, Teaching assistant, the First Clinical Medical College of Hebei North University, Zhangjiakou 075000, Hebei Province, China guyantianya@sina.com

Abstract:

:BACKGROUND: Research in recent years suggests that the self-renewal and multi-directional differentiation potency of human umbilical cord blood derived mesenchymal stem cells (UCB-MSCs) offer basic condition to cell transplantation treatment. Moreover, their immunoloregulation function enormously expands the direction and limits cell transplantation treatment.
OBJECTIVE: To retrospectively analyze the immunoloregulation and human UCB-MSCs transplantation.
METHODS: The key word “umbilical cord blood-derived mesenchymal stem cells” was used to search in Pubmed database and CNKI database from January 2008 to June 2011 in English and Chinese using computer. The preliminary screening was made through reading the title and abstract. The articles with unrelated contents, repetitive and Meta analysis were excluded. 30 papers of pertinent literature to be published in the near future or published in the authority magazine were selected to review.
RESULTS AND CONCLUSION: Human UCB-MSCs have the similar self-renewal and multi-directional differentiation potency with the bone marrow derived mesenchymal stem cells. Through cell transplantation technique, human UCB-MSCs show powerful potentiality in diabetes mellitus treatment, neural degeneration disease like Alzheimer’s disease and Parkinson’s disease and injury of nerve retreatment. Meanwhile, human UCB-MSCs have immunoregulatory ettects, they can lower immune reaction through down regulation of T-cells. We also get some advancements on several immunological diseases such as cell therapy of graft versus host disease and lupus nephritis.
 

CLC Number: